Drug interactions between posaconazole and rifapentine
| Results for the following 2 drugs: |
|---|
| posaconazole |
| rifapentine |
Interactions between your selected drugs
rifapentine ↔ posaconazole
Applies to:rifapentine and posaconazole
GENERALLY AVOID: Coadministration with a rifamycin may result in decreased plasma concentrations of posaconazole. The mechanism is induction of posaconazole clearance via the UDP-glucuronosyltransferase glucuronidation and P-glycoprotein efflux pathways. According to product labeling, administration of posaconazole (200 mg tablets once a day for 10 days) with rifabutin (300 mg once a day for 17 days) resulted in reduced posaconazole mean peak plasma concentration (Cmax) by 57% and systemic exposure (AUC) by 51%. Treatment failure could result. Conversely, posaconazole is an inhibitor of CYP450 3A4 and can increase the plasma levels of rifabutin, which is thought to be partially metabolized by the isoenzyme. Rifabutin Cmax rose by 31% and AUC by 72% during coadministration of posaconazole.
MANAGEMENT: Use of posaconazole in combination with a rifamycin should generally be avoided unless the potential benefit outweighs the risk. If coadministration is necessary, patient response to the antifungal agent must be closely monitored. When administered with rifabutin, close clinical and laboratory monitoring for rifabutin toxicity including leukopenia, uveitis, arthralgias, and skin discoloration are also recommended.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
